{
    "ticker": "MBRX",
    "name": "MabVax Therapeutics Holdings, Inc.",
    "description": "MabVax Therapeutics Holdings, Inc. is a biotechnology company focused on the development of immunotherapy-based therapies for cancer. Founded in 2014, MabVax is dedicated to advancing the treatment of cancer through innovative antibody-based technologies and targeted therapies. The company leverages its proprietary platform to develop therapeutic monoclonal antibodies that target specific cancer antigens, aiming to create safer and more effective treatment options for patients. MabVax's lead product candidates are designed to treat various types of solid tumors, with a special emphasis on pancreatic and other gastrointestinal cancers. The company\u2019s approach includes harnessing the body's immune system to fight cancer, thereby potentially reducing the side effects associated with traditional cancer treatments. MabVax is actively engaged in clinical trials to evaluate the efficacy and safety of its therapies, aiming to bring new hope to patients facing challenging diagnoses. With a strong commitment to scientific research and collaboration with leading academic institutions, MabVax strives to make a significant impact in the field of oncology.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2014",
    "website": "http://www.mabvax.com",
    "ceo": "David Hansen",
    "social_media": {
        "twitter": "https://twitter.com/MabVax",
        "linkedin": "https://www.linkedin.com/company/mabvax-therapeutics/"
    },
    "investor_relations": "http://www.mabvax.com/investor-relations",
    "key_executives": [
        {
            "name": "David Hansen",
            "position": "CEO"
        },
        {
            "name": "Rita D. Kahn",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "MVT-5873",
                "MVT-201"
            ]
        }
    ],
    "seo": {
        "meta_title": "MabVax Therapeutics Holdings, Inc. | Cancer Immunotherapy",
        "meta_description": "Explore MabVax Therapeutics, a leader in cancer immunotherapy focused on monoclonal antibody development to treat solid tumors. Discover our innovative approaches and clinical trials.",
        "keywords": [
            "MabVax",
            "Cancer Therapy",
            "Immunotherapy",
            "Monoclonal Antibodies",
            "Biotechnology",
            "Oncology"
        ]
    },
    "faq": [
        {
            "question": "What does MabVax specialize in?",
            "answer": "MabVax specializes in developing immunotherapy-based treatments for cancer, particularly targeting solid tumors."
        },
        {
            "question": "Who is the CEO of MabVax?",
            "answer": "The CEO of MabVax is David Hansen."
        },
        {
            "question": "Where is MabVax headquartered?",
            "answer": "MabVax is headquartered in San Diego, California, USA."
        },
        {
            "question": "What are MabVax's main product candidates?",
            "answer": "MabVax's main product candidates include MVT-5873 and MVT-201, which are designed to treat various types of cancer."
        },
        {
            "question": "When was MabVax founded?",
            "answer": "MabVax was founded in 2014."
        }
    ],
    "competitors": [
        "AMGN",
        "REGN",
        "SRPT"
    ],
    "related_stocks": [
        "GILD",
        "BMY",
        "JNJ",
        "PFE"
    ]
}